Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Indrajeet Kumar

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Antioxidants (Basel, Switzerland)|March 25, 2022
Algal Metabolites Can Be an Immune Booster against COVID-19 PandemicAjay Kumar, Rahul Prasad Singh, Indrajeet Kumar, et al.
The Lancet. Infectious Diseases|October 26, 2017
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trialSirintip Sricharoenchai, Chukiat Sirivichayakul, Kulkanya Chokephaibulkit, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 14, 2019
Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical TrialGeraldine Blanchard Rohner, Olga Chatzis, Pailinrut Chinwangso, et al.
Eclinicalmedicine|August 13, 2021
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP<sub>gen</sub> or combined TdaP<sub>gen</sub> vaccinesPunnee Pitisuttithum, Jittima Dhitavat, Chukiat Sirivichayakul, et al.
The Lancet. Infectious Diseases|September 30, 2018
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trialPunnee Pitisuttithum, Kulkanya Chokephaibulkit, Chukiat Sirivichayakul, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Antioxidants (Basel, Switzerland)|March 25, 2022
Algal Metabolites Can Be an Immune Booster against COVID-19 PandemicAjay Kumar, Rahul Prasad Singh, Indrajeet Kumar, et al.
The Lancet. Infectious Diseases|October 26, 2017
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trialSirintip Sricharoenchai, Chukiat Sirivichayakul, Kulkanya Chokephaibulkit, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 14, 2019
Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical TrialGeraldine Blanchard Rohner, Olga Chatzis, Pailinrut Chinwangso, et al.
Eclinicalmedicine|August 13, 2021
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP<sub>gen</sub> or combined TdaP<sub>gen</sub> vaccinesPunnee Pitisuttithum, Jittima Dhitavat, Chukiat Sirivichayakul, et al.
The Lancet. Infectious Diseases|September 30, 2018
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trialPunnee Pitisuttithum, Kulkanya Chokephaibulkit, Chukiat Sirivichayakul, et al.
Pageof 4